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This study was undertaken to assess the frequency of significant esopha- 
geal involvement in the Z011inger-EIiison syndrome (ZES). In a consecu- 
tive series of 24 patients with this disease, 9 (37%) showed endoscopic 
evidence of acid-induced esophageal lesions ranging from erosive inflam- 
mation to ulceration with massiv e bleeding, severe stricture formation, 
and perforation. In 3 cases, pronounced esophagitis was known 1-5 year s 
before the underlying disease was diagnosed. Severe esophageal compli- 
cations developed despite treatment with antisecretory drugs. It is em- 
phasized that the best way to limit such complications is by excision of the 
underlying gastrin-secreting tumor(s) when possible. 
Esophageal involvement by acid-induced disease is an aspect of 
the Zollinger-Ellison syndrome (ZES) that tends to be over- 
shadowed bY other more urgent problems and has received very 
little attention in the medical literature. It was not until 1979 
that an association between ZES and gastroesophageal reflux 
was suggested [1], and subsequent comments on this subject are 
few [2-4]. The accumulated experience from a substantial 
number of ZES patients referred to the University of Michigan 
Medical Center has shown that gastroesophageal reflux is not 
only a common and sometimes initial manifestation of the 
disease, but also a potentially serious threat. The purpose of 
this report is to emphasize these facts, and to underline that the 
best way to limit the complications is by excision of the 
underlying gastrin-secreting tumor(s) when possible. 
Material and Methods 
Forty-two patients with ZES were referred to the University of 
Michigan Medical Center in Ann Arbor from 1962 through 1988. 
Eighteen patients admitted before 1983 were included in a 
previous study on esophageal disease from a radiologic point of 
view [4], and these patients will not be considered further in this 
report. The additional 24 patients forming the basis of this study 
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included 11 women, 12 men, and 1 boy with an age range from 
11 to 83 years at the time of diagnosis (median, 46 years). In 3 
patients, ZES occurred as part of multiple endocrine neoplasia 
type i (MEN I). Histologically verified gastrinomas were re- 
moved in 15 cases. The primary tumor(s) were located in the 
pancreas in 6 patients, in the duodenum in 7 patients, and in the 
liver in 1 patient. A solitary lymph node containing gastrinoma 
was the only tumor manifestation discovered in 1 patient. In  the 
remaining 9 cases, the diagnosis was based on hypergastrin- 
emia, positive secretin-stimulation test, and hyperchlorhydria. 
Information regarding signs of esophageal disease was obtained 
by review of the medical records at the University Hospital in 
Ann Arbor .  
Results 
Endoscopic examination of the esophagus, performed before 
gastric resection whenever this had been done, was docu- 
mented in 18 cases. Thirteen of these patients showed evidence 
of acid-induced esophagitis which was associated with ulcer- 
ations in 9 cases. In 3 cases, esophagitis was diagnosed endo- 
scopically 1-5 years before the nature of the underlying disease 
was realized. Three patients developed severe complications as 
follows. 
A 42-year-old woman had a history of intermittent epigastric 
pain for many years when she developed symptoms of upper 
gastrointestinal bleeding. The origi n of this appeared to be a 
duodenal ulcer. At endoscopic examination, it was noted that 
she also had severe esophagitis. Treatment with cimetidine was 
started. Three years later, while taking 300 mg of cimetidine 5 
times a day, she was admitted as an emergency because of 
sudden profound weakness, hematemesis, and a hemoglobin of 
only 7.5 g percent. Endoscopy revealed an esophageal ulcer to 
be the source of bleeding, whereas there were no changes but 
erythema in the duodenum. After blood replacement, the pa- 
tient was referred to the University Hospital for evaluation of 
possible ZES and this diagnosis was confirmed biochemically. 
Her Subsequent treatment has been given elsewhere. 
A 19-year-old woman was referred to the University Hospital 
for treatment of malignant gastrinoma with liver metastases. 
Previous endoscopic examination elsewhere had shown severe 
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ulcerating esophagitis in addition to a bleeding duodenal ulcer 
that led to exploration and discovery of her disease. One year 
later, while taking cimetidine and antacids, she began treatment 
with somatostatin analog (201-995) 250 mcg twice a day. After 
having been on this regimen for 6 months, the patient com- 
plained of  increasing heartburn and dysphagia. Endoscopy 
showed persistent severe esophagitis complicated by stricture. 
This stricture has required repeated dilatations to permit oral 
alimentation. 
A 45-year-old woman with MEN I was admitted to the 
Division of Endocrinology and Metabolism at the University 
Hospital where a suspected ZES was confirmed biochemically. 
Endoscopic examination showed severe esophageal changes 
with widespread inflammation and multiple ulcers. At the time 
of admission, the patient was taking ranitidine 150 mg twice a 
day. This medication was changed to famotidine 40 mg 4 times 
a day. Because of persistent symptoms, somatostatin analog 
150 mcg 3 times a day was added to her therapeutic program. 
This reduced her basal acid output to normal levels. Neverthe- 
less, she was readmitted 1 month later because of severe 
heartburn and dysphagia. Somatostatin analog was increased to 
150 mcg 4 times a day, and famotidine to 60 mg 4 times a day. 
Furthermore, metoclopramide was added in incremental doses 
until the patient complained of drowsiness; however, she expe- 
rienced progressive dysphagia and a 15-kg weight loss during 
the following 6 weeks. Roentgen examination showed an esoph- 
ageal stricture with narrowing of the lumen to 5 mm. Subse- 
quently, she underwent several painful dilatations to be able to 
continue oral alimentation. At this point, surgical advice was 
requested and the patient was recommended gastrinoma local- 
ization studies; however, before this could be done, she vom- 
ited, resulting in esophageal perforation and emptying of gastric 
contents into the chest. The diagnosis was established immedi- 
ately and emergency esophagectomy and pleural drainage were 
performed. Exploratory laparatomy was also done at this 
occasion and 3 duodenal gastrinomas were removed along with 
2 peripancreatic lymph node metastases. Her serum gastrin 
levels, which were up to 10,000 pg/ml before the operation, 
subsequently fell to normal values and have remained so for 9 
months at present, even with secretin stimulation. Two months 
after the perforation, a cervical esophagogastrostomy was 
performed allowing restoration of oral alimentation (the colon 
could not be used because of previous abdominal surgery). She 
is currently doing well without any gastrointestinal symptoms. 
Discussion 
No less than 9 of 24 ZES patients referred to the University of 
Michigan Medical Center during the last 6 years were found to 
have ulcerating esophagitis. This figure (37%) is in good agree- 
ment with findings in a previous prospective study of gastro- 
esophageal reflux in ZES, from which it was estimated that at 
least one-third of  such patients will develop significant esoph- 
ageal disease [2]. An important observation in that study, as 
well as in the cases reported here, is that reflux symptoms may, 
in fact, be the first sign of ZES. ZES should, therefore, be kept 
in mind as a differential diagnosis in patients with intractable 
heartburn. 
The importance of paying attention to esophageal involve- 
ment in ZES is emphasized by the serious complications in 3 of 
our patients who developed massive bleeding, severe stricture 
formation, and perforation, respectively. Another potential 
threat is the risk of malignant transformation in the Barrett's 
mucosa that occurs in the esophagus as a result of chronic acid 
reflux [3]. A most significant fact relating to esophageal disease 
is that patients with ZES show a high prevalence of gastro- 
esophageal reflux despite long-term treatment with cimetidine 
[2]. It is also noteworthy that 2 of our patients showed progres- 
sive esophageal disease with severe complications while being 
on treatment with somatostatin analog for several months. 
The development of serious esophageal complications de- 
spite antisecretory drug therapy emphasizes that the prime goal 
of treatment in patients with ZES is to eradicate the underlying 
gastrin-secreting tumor(s). These patients should be treated 
surgically as early as possible in the course of the disease, 
before metastases have developed [5]. A problem associated 
with early surgical intervention in ZES is that many gastrino- 
mas will be too small to be localized by any of the imaging 
techniques that are available today; however, this problem can 
be reduced by percutaneous transhepatic venous sampling 
(PTVS) for gastrin gradient mapping of the portal drainage area. 
By this technique, gastrinomas measuring only 2-3 mm were 
localized in 4 of our patients [6]. We also use PTVS in the 
evaluation of MEN patients with ZES. Despite the morpholog- 
ically diffuse nature of the pancreatic islet changes in such 
patients [7], the clinically significant gastrin secretion is some- 
times localized to a certain region which can be removed by 
less-than-total pancreatectomy. It is our experience that se- 
lected MEN patients may benefit clinically by local excision of 
gastrinomas, even though not biochemically "cured"  of their 
pancreatic disease [8]. Serious esophageal complications would 
have been prevented in one of our MEN patients by earlier 
referral for localization studies and exploration. After removal 
of 3 duodenal gastrinomas along with 2 lymph node metastases, 
her serum gastrin levels--which were up to 10,000 pg/ml before 
the operation--fell to normal values and have remained so for 9 
months at present, even with secretin stimulation. 
In conclusion, this study shows that significant esophageal 
involvement by acid-induced disease is common in ZES and 
may cause serious complications. Gastroesophageal reflux is 
not eliminated by antisecretory drugs in these patients, and it is 
emphasized that the prime goal of the treatment is to remove 
the underlying gastrin-secreting tumor(s) as early as possible in 
the course of the disease, before metastases develop. 
R~sum~ 
Nous avons entrepris cette 6tude pour 6tablir la fr6quence de 
participation oesophagienne dans le syndrome de Zollinger- 
Ellison. Pour une s6rie de 24 patients pr6sentant cette maladie, 
9 (37%) avaient A l'endoscopie des 16sions oesophagiennes dues 
l'acidit6 allant de l'6rosion inflammatoire A l'ulc6ration avec 
saignement important, st6nose s6v6re, et perforation. Dans 3 
cas, une oesophagite importante 6tait connue 1-5 ans avant que 
la maladie sous-jacente soit diagnostiqu6e. Des complications 
oesophagiennes s6v6res se sont produites malgr~ le traitement 
antis6cr6toire. Nous insistons sur le fait que le meilleur moyen 
de limiter ces complications est d'exciser chaque lois que 
possible la ou les tumeurs sous-jacentes s6cr6tant la gastrine. 
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Resumen 
E1 presente estudio fue emprendido con el prop6sito de deter- 
minar la frecuencia de afecci6n ~icido p6ptica significativa del 
es6fago en pacientes con sindrome de Zollinger-Ellison. En una 
serie de 24 pacientes consecutivos con esta enfermedad, 9 
(37%) exhibieron evidencia endosc6pica de lesiones esofiigicas 
inducidas por ~icido, las cuales variaron entre inflamaci6n 
erosiva y ulceraci6n con sangrado masivo, estrechez severa, y 
perforaci6n. En 3 pacientes se conocfa la existencia de esofagi- 
tis severa entre 1 y 5 afios antes del diagn6stico de la enfer- 
medad de base. Se desarrollaron graves complicaciones esof- 
~igicas a pesar del tratamiento con drogas antisecretorias en 3 
pacientes. Se hace enfasis en que la mejor manera de disminuir 
tales complicaciones es mediante la resecci6n del tumor(es) 
secretor de gastrina, cuando eilo sea posible. 
References  
1. McCallum, R.W., Walsh, J.H.: Relationship between lower esoph- 
ageal sphincter pressure and serum gastrin concentration in 
Zollinger-Ellison syndrome and other clinical settings. Gastroenter- 
ology 76:76, 1979 
2. Richter, J.E., Pandol, S.J., Castell, D.O., McCarthy, D.M.: Gastro- 
esophageal reflux disease in the Zollinger-Ellison syndrome. Ann. 
Intern. Med. 95:37, 1981 
3. Karl, T.R., Pindyck, F., Sicular, A.: Zollinger-Ellison syndrome 
with esophagitis and Barrett mucosa. Am. J. Gastroenterol. 76:611, 
1983 
4. Agha, F.: Esophageal involvement in Zollinger-Ellison syndrome. 
Am. J. Roentgenol. 144: 721, 1985 
5. Wolfe, M.M., Jensen, R.T.: Zollinger-Ellison syndrome. Current 
concepts in diagnosis and treatment. N. Engl. J. Med. 317:1200, 1987 
6. Thompson, N.W., Vinik, A.I., Eckhauser, F.E.: Microgastrinomas 
of the duodenum: A cause of failed operations for the Zollinger- 
Ellison syndrome. Ann. Surg. 209:396, 1989 
7. Thompson, N.W., Lloyd, R.V., Nishiyama, R.H., Vinik, A.I., 
Strodel, W.E., Allo, M.D., Eckhauser, F.E., Talpos, G., Mervak, 
T.: MEN I pancreas: A histological and immunohistochemical 
study. World J. Surg. 8:561, 1984 
8. Thompson, N.W., Bondeson, A.-G., Bondeson, L., Vinik, A.I.: The 
surgical treatment of gastrinoma in MEN I syndrome patients. 
Surgery 106:1081, 1989 
Invited Commentary 
Stanley R. Fr iesen,  M.D.  
Department of Surgery, The University of Kansas Medical Center, 
Kansas City, Kansas, U.S.A. 
Years ago, Lester Dragstedt often made a comment that "man 
does not readily digest his own stomach." Yet those areas at 
either end of the stomach, the esophagus and duodenum, more 
easily yield to acid-peptic ulceration. The esophagus, in partic- 
ular, is protected by a lower esophageal sphincter (LES) and a 
tough squamous and mucous lining. Another surgeon-physiol- 
ogist, Alan Thai, demonstrated experimentally that the 
squamous epithelium of the cat 's  esophagus succumbed by 
erosion-ulceration within 20 minutes to the dripping of human 
gastric juice on it. It is not too surprising that the marked gastric 
acid hypersecretion that is one of the cardinal features of the 
Zollinger-Ellison syndrome (ZES), which causes ulceration as 
far distant as the jejunum, might also wreak havoc in the 
esophagus. 
It is important that the authors emphasize the occurrence of 
esophageal complications in the ZES; the gamut of symptoms 
and pathological changes in the esophagus are easily over- 
looked, being frequently overshadowed by the abdominal find- 
ings, unless upper endoscopy is routinely done. The intermit- 
tent healing Of erosive esophagitis and ulceration, with or 
without receptor-blockade treatment, may result in stricture 
formation that can be rigidly diffuse along the whole esophagus; 
this makes oral alimentation (and the obtaining of gastric acid 
for analyses) impossible. 
The exact mechanism of the pathophysiology of esophageal 
involvement is not clear; the authors do not enlighten us on that 
point, although by implication they seem to point the finger at 
the action of the hypergastrinemia, per se, on the LES and/or 
the esophagus. This they support by their observations that 
reflux and esophagitis occur with hypergastrinemia even when 
patients are presumed to have a measure of control of acid 
hypersecretion while being treated with receptor-blockade and/ 
or a somatostatin analogue. It is known that gastrin in pharma- 
cologic doses or with supraphysiologic circulating levels causes 
contraction of the LES. Teleologically, this would appear to 
constitute a protective mechanism for the esophagus. On the 
other hand, the normal sustained tonic contraction of the LES 
is mediated by intracellular calcium in the sphincter muscle that 
can be influenced by the inhibitory relaxing action of the 
neurotransmitter, vasoactive intestinal peptide (VIP) from the 
myenteric plexus. This effect is secondary to the muscarinic 
action of cholinergic receptors. In patients with esophagitis, the 
pressure at the LES is reduced, allowing reflux due to sponta- 
neous relaxation. This is associated with an increased density of 
VIP-containing neurones in the sphincter of these patients. In 
ZES patients with hypergastrinemia, it is more reasonable to 
invoke other mechanisms for the occurrence of esophageal 
complications, one of which is the massive hypersecretion of 
gastric acid that simply overwhelms sphincter and mucous 
protection. Furthermore, duodenal ulceration in these patients 
frequently results in gastric outlet obstruction due either to 
duodenal narrowing or pylorospasm, both of which lead to 
gastric regurgitation into the esophagus. 
There are some clinical observations that suggest yet a third 
pathophysiologic mechanism for the development of esopha- 
geal dysfunction. There are at least 2 patients who have 
unaccountably developed incapacitating regurgitation, without 
mechanical obstruction, after total gastrectomy, which cer- 
tainly abolishes acid secretion and the lower esophageal sphinc- 
ter as well. In one of these patients who had had a total 
gastrectomy for hepatic metastatic gastrinomas with persis- 
tently marked hypergastrinemia, this debilitating complication 
developed postoperatively for the first time. There was no 
anastomotic obstruction and the regurgitation persisted even 
after surgical revision of the Roux-en-Y esophagojejunostomy 
